

Medicare Part D Formularies (PDP only, excluding SNP, for 30-day supply)**(Table 4)**

Report on CMS formulary files (January 2025 and January 2024). All calculations are percentages of formularies, except co-pay, which is in dollars, and coinsurance, which is a percentage of drug price.

Drugs selected for Medicare Drug Price Negotiation in 2026

Non-specialty	2025			2025			2025			2025		
		Change vs. 2024	Without prior authorization	Change vs. 2024	Tier 3 or lower	Change vs. 2024		Average co-pay		Change vs. 2024		
Generic (brand name)	On formulary											
apixaban (Eliquis)		100	0	100	0	100	5	\$ 45		€ (1)		
dapagliflozin propanediol (Farxiga)		100	20	100	0	78	16	\$ 46		\$ 14		
empagliflozin (Jardiance)		100	2	100	0	100	15	\$ 45		\$ 12		
insulin aspart (Fiasp/Novolog)		66	-4	100	0	100	14	\$ 46		€ 1		
rivaroxaban (Xarelto)		100	0	100	0	100	0	\$ 45		\$ -		
sacubitril/valsartan (Entresto)		100	0	100	0	100	0	\$ 45		\$ 0		
sitagliptin phosphate (Januvia)		93	-2	100	0	100	16	\$ 45		\$ 13		

Specialty	On formulary	Change vs. 2024	Without prior authorization	Change vs. 2024	Tier 3 or lower	Change vs. 2024	Average coinsurance	Change vs. 2024
etanercept (Enbrel)		78	-17	0	0	0	27	-1
ibrutinib (Imbruvica)		100	0	0	0	0	27	0
ustekinumab (Stelara)		100	20	0	0	0	27	-1

Drugs selected for Medicare Drug Price Negotiation in 2027

Non-specialty	2025	2024	2025	2024	2025	2024	2025	2024
		Change vs. 2024	Without prior authorization	Change vs. 2024	Tier 3 or lower	Change vs. 2024	Average co-pay	Change vs. 2024
Generic (brand name)	On formulary							
fluticasone/umeclidin/vilanter (Trelegy Ellipta)	100	10	100	0	100	0	\$ 45	\$ 0
fluticasone/vilanterol (Breo Ellipta)	100	0	100	0	100	0	\$ 45	\$ 0
linaclotide (Linzess)	100	0	100	0	89	27	\$ 45	\$ 1
linagliptin (Tradjenta)	94	6	100	0	100	17	\$ 45	\$ 13
semaglutide (Ozempic)	93	8	0	-18	94	6	\$ 45	\$ 10
sitagliptin phos/fetformin HCl (Janumet)	93	-2	100	0	100	16	\$ 45	\$ 13

Medicare Part D Formularies (PDP only, excluding SNP, for 30-day supply)**(Table 4)**

Report on CMS formulary files (January 2025 and January 2024). All calculations are percentages of formularies, except for co-pay, which is in dollars, and coinsurance, which is a percentage of drug price.

Specialty	On formulary	Change vs. 2024	Without prior author- ization	Change vs. 2024	Tier 3 or lower	Change vs. 2024	Average coinsurance	Change vs. 2024
acalabrutinib (Calquence)	100	0	0	0	0	0	27	0
apremilast (Otezla)	70	-30	0	0	0	0	27	-1
cariprazine HCl (Vraylar)	100	0	73	4	0	0	38	-8
deutetrabenazine (Austedo)	78	5	0	0	0	0	27	0
enzalutamide (Xtandi)	100	0	0	0	0	0	27	-2
nintedanib esylate (Ofev)	100	0	0	0	0	0	27	0
palbociclib (Ibrance)	100	0	0	0	0	0	27	0
pomalidomide (Pomalyst)	100	0	0	0	0	0	27	0
rifaximin (Xifaxan)	100	0	0	-14	0	0	34	1